Studies from Indiana University School of Medicine Provide New Data on Cirrhosis (Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium In Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal...).

A recent study conducted by researchers at Indiana University School of Medicine focused on the pharmacokinetic, safety, and pharmacodynamic profiles of Saroglitazar Magnesium in participants with cholestatic cirrhosis and hepatic impairment, as well as those with severe renal impairment. The research found that Saroglitazar was safe and well-tolerated in participants with mild hepatic impairment and severe renal impairment, with no major pharmacokinetic changes. The study was supported by financial assistance from Zydus Therapeutics Inc. For more information, readers can refer to the original article published in Clinical Pharmacology & Therapeutics. [Extracted from the article]